Abstract
Despite the questions and barriers, the incorporation of molecular therapy into treatment regimens in endometrial cancer is an exciting area of investigation with the potential to improve outcomes. Outside of the development of a reliable screening test for endometrial cancer, converting the disease to a chronic state and improving progression-free survival is our best hope to reverse the concerning trend of decreasing 5-year survival for this disease.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Chemotherapy, Adjuvant
-
Endometrial Neoplasms* / complications
-
Endometrial Neoplasms* / diagnosis
-
Endometrial Neoplasms* / therapy
-
Female
-
Humans
-
Hysterectomy*
-
Lymph Node Excision
-
Middle Aged
-
Molecular Targeted Therapy* / methods
-
Molecular Targeted Therapy* / trends
-
Obesity / complications
-
Postmenopause
-
Prognosis
-
Risk Factors
-
United States / epidemiology
-
Uterine Hemorrhage / etiology